CD Genomics offers specialized Microbial Short-Chain Fatty Acid (SCFA) Analysis with high specificity and accuracy. Utilizing advanced GC-MS technology, we provide precise identification and quantification of SCFAs, delivering rapid results through optimized chromatographic methods. This analysis is essential for understanding gut health, metabolic disorders, and the role of microbiota in various diseases.
SCFAs are critical metabolites produced through the fermentation of dietary fibers and resistant starches by the gut microbiota. The primary SCFAs include acetate, propionate, and butyrate. These fatty acids play indispensable roles in various physiological processes: they supply energy to colonocytes, fortify gut barrier integrity, modulate immune functionality, and influence systemic metabolism. The presence and activity of SCFAs contribute significantly to maintaining a healthy gut environment and are intricately involved in metabolic regulations. Moreover, SCFAs are associated with several health conditions, including inflammatory bowel disease and metabolic syndrome, underscoring their importance in preserving overall health and preventing disease.
The analysis of SCFAs entails quantifying their concentrations and types within biological samples such as feces, blood, or tissues. This type of analysis is fundamental for providing insights into an individual's metabolic health and the condition of their gut microbiota.
Techniques for SCFA Analysis:
These methodologies collectively contribute to the comprehensive understanding of SCFA profiles, reflecting the metabolic status and gut microbiota health of individuals.
The applications of SCFA analysis include, but are not limited to, the following areas:
CD Genomics delivers an extensive service for profiling microbial SCFAs integrated with genome-based analysis. The procedure starts with converting fatty acids into volatile derivatives, facilitating their separation. Utilizing longer columns and an elevated carrier gas velocity, we achieve rapid separation and can run the analysis in a continuous workflow. Our cutting-edge GC/MS platform enhances the sensitivity, selectivity, and reliability of the analysis, ensuring precise and dependable results.
What We Offer
Analyzable Short-Chain Fatty Acids include but are not limited to:
Acetic Acid | Propionic Acid | Butyric Acid | Isobutyric Acid |
Valeric Acid | 2-Methylbutyric Acid | Isovaleric Acid | Caproic Acid |
Isopropionic Acid | 3-Methylvaleric Acid | 2-Methylvaleric Acid | 3-Hydroxyisovaleric Acid |
Lactic Acid | Malonate | Succinic Acid | Pentanedioic Acid |
CD Genomics delivers a standardized review and research kit that can be configured according to the purposes of the research.
Core Databases | Electron ionization MS library |
National Institute of Standards and Technology mass spectral library |
Analysis Type | Analysis Content |
---|---|
Quality Control | QC RSD |
Differential Analysis | Univariate Statistical Analysis, Box Plot, Correlation Analysis |
Functional Analysis | Hierarchical Cluster Analysis, KEGG Analysis |
Bioinformatics Analysis | Regression Analysis, Trend Cluster Analysis, Machine Learning Analysis |
Note: The above content includes only a portion of the bioinformatics analysis. For more information or to customize the analysis, please contact us directly.
Note:
Partial results of our SCFA analysis service are shown below:
Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease
Journal: Neurology
Impact factor: 11.8
Published: February 22, 2022
Background
Parkinson's disease (PD) is a prevalent neurological disorder. Emerging research indicates that gastrointestinal symptoms may precede motor symptoms by several decades. Compared to healthy individuals, patients with PD exhibit a distinct gut microbiota composition, with alterations in the gut microbiome being correlated with the severity and progression of the disease. SCFAs, which are primary metabolites produced by gut microbiota through the fermentation of dietary fibers, are hypothesized to play a pivotal role in the gut-brain axis. However, comprehensive studies investigating the levels of SCFAs in fecal and plasma samples remain lacking.
Materials & Methods
Sample preparation:
Method:
Data Analysis:
Results
Employing gas chromatography-mass spectrometry (GC-MS) for the quantification of SCFAs in fecal and plasma samples, the research unveiled marked differences in SCFA profiles between Parkinson's disease (PD) patients and healthy individuals. The comprehensive analysis unearthed significant correlations between SCFA levels and various aspects of PD, including motor dysfunction, cognitive decline, and gut microbiota composition. Notably, decreased levels of fecal SCFAs coupled with elevated plasma concentrations of propionate were linked to worsened motor abilities. Furthermore, diminished fecal SCFAs alongside increased plasma levels of butyrate and valerate were associated with cognitive deficits. Alterations in the abundance of specific gut microbial taxa were also connected to variations in SCFA levels in both fecal and plasma matrices. These insights propose that SCFAs could serve as critical biomarkers for gauging the severity of PD, enhancing the comprehension of the complex gut-brain interactions in these patients.
Figure 1 Comparison of Fecal Levels of Short Chain Fatty Acids in Patients With PD and Healthy Controls.
Figure 2 ROC Curves for Distinguishing Patients With PD From Controls and Correlations Between SCFA Levels and Clinical Motor Symptom Severity in Patients With PD.
Conclusions
This study is the first to link plasma and fecal SCFAs with Parkinson's disease (PD) severity and gut microbiota changes. PD patients had lower fecal but higher plasma SCFAs compared to controls. Reduced fecal SCFAs were associated with worse motor and cognitive symptoms. These findings suggest SCFAs may serve as biomarkers for PD. Limitations include indirect SCFA measurement and lack of gut permeability data. Further research is needed to explore SCFAs' role in PD.
Reference
Chen Szu-Ju,Chen Chieh-Chang,Liao Hsin-Yu et al. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients .Neurology, 2022.
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.
Please fill out the form below: ×